Document is current
Any future updates will be listed below
-
Authors
Shiraishi, Takuya
Ikeda, Koji
Tsukada, Yuichiro
Nishizawa, Yuji
Sasaki, Takeshi
Ito, Masaaki
Kojima, Motohiro
Ishii, Genichiro
Tsumura, Ryo
Saijou, Sinji
Koga, Yoshikatsu
Yasunaga, Masahiro
Matsumura, Yasuhiro
- License Information
-
More Information
Article History
Received: 1 December 2020
Accepted: 15 March 2021
First Online: 23 March 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients who were obtained surgically resected frozen tissue specimens used by this study gave informed consent, and the consent was obtained in writing. All experimental protocols were approved by the Committee for Animal Experimentation of the National Cancer Center. This study was carried out in compliance with the ARRIVE guidelines. This study was approved by our institutional review board (National Cancer Center Hospital Approval no. K2012–001).
: Not applicable.
: YM is co-founder, shareholder and Board Member of RIN Institute Inc., the company that owns the anti-TMEM180 antibody. MY is shareholder of RIN Institute Inc. SS is an employee of RIN Institute Inc. Others declare no competing interests.
